OAC Meets with Trump Administration to Support CMS Proposed Rule
in OAC Blog on April 4, 2025

2025 has already been a busy year for the Obesity Action Coalition (OAC), especially in our advocacy work to improve access to obesity care. One of the most significant milestones from 2024 was the Centers for Medicare and Medicaid Services (CMS) Proposed Rule, which would expand coverage for obesity medications under Medicare and Medicaid. With
Read Article

80+ Organizations Urge Trump Administration to Cut Spending & Reward Innovation by Expanding Access to Obesity Medications
in 2025 News Releases, OAC Blog, OAC Newsroom on

FOR IMMEDIATE RELEASE: 80+ Organizations Urge Trump Administration to Cut Spending & Reward Innovation by Expanding Access to Obesity Medications A Centers for Medicare & Medicaid Services (CMS) Proposed Rule Would Address Outdated Policy Constraints & Expand Access to Innovative Treatments for Obesity Tampa, FL (April 3, 2025) — Today, the Obesity Action Coalition (OAC)
Read Article

Why OAC Warns Against Compounded GLP-1 Medications
in OAC Blog on March 24, 2025

by Joe Nadglowski, OAC President and CEO For the past 20 years, the Obesity Action Coalition (OAC) has advocated for evidence-based treatments for the disease of obesity. In 2010, OAC began challenging the FDA to take serious action in approving new medicines for obesity treatment. Fast forward to today, and you see we now have
Read Article

A Win for Obesity Care: What the New CMS Proposed Rule Means for Patients
in OAC Blog on December 10, 2024

Under current law, Medicare’s prescription drug benefit (Part D) excludes “agents when used for anorexia, weight loss, or weight gain”. This exclusion has prevented Medicare from covering obesity medications and has allowed Medicaid plans to opt out of providing such coverage. For more than a decade, the OAC has pursued both legislative and regulatory pathways
Read Article